Location History:
- München, DE (2002)
- Munich, DE (2013 - 2021)
Company Filing History:
6 out of 132 
1 out of 57 Years Active: 2002-2021
Title: The Innovative Contributions of Kay Brinkmann
Introduction
Kay Brinkmann is a notable inventor based in Munich, Germany. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of 7 patents, Brinkmann's work focuses on enhancing immune responses using recombinant poxviruses.
Latest Patents
One of Brinkmann's latest patents is the "PR13.5 promoter for robust T-cell and antibody responses." This invention encompasses recombinant poxviruses, specifically modified Vaccinia Ankara (MVA) viruses, which include a Pr13.5 promoter operably linked to a nucleotide sequence encoding an antigen. The invention aims to induce strong CD8 T cell and antibody responses to specific antigens through immunizations of the recombinant MVA in mammals, particularly humans.
Another significant patent is related to "Poxviral vectors for low antibody response after a first priming immunization." This invention focuses on compositions and methods to induce a strong CD8 T cell response to a specific antigenic determinant without eliciting a significant antibody response after the initial priming immunization. The method involves administering a recombinant poxviral vector that includes a transcriptional control element linked to a nucleotide sequence encoding the antigenic determinant.
Career Highlights
Throughout his career, Kay Brinkmann has worked with prominent companies in the biotechnology sector. Notable among these are Bavarian Nordic A/S and Aventis Research & Technologies GmbH & Co. KG. His work in these organizations has contributed to advancements in vaccine development and immunotherapy.
Collaborations
Brinkmann has collaborated with esteemed colleagues, including Jürgen Hausmann and Karen Baur. These partnerships have fostered innovation and have been instrumental in the development of his patented technologies.
Conclusion
Kay Brinkmann's contributions to immunology through his patents demonstrate his commitment to advancing medical science. His innovative approaches to enhancing immune responses have the potential to significantly impact vaccine development and therapeutic strategies.